Results 81 to 90 of about 5,020 (198)

NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis

British Journal of Haematology, EarlyView.
R. Van Dijck, M. ter Borg, B. van der Holt, A. E. C. Broers, M. D. Hazenberg, J. J. Cornelissen, N. P. M. Schaap, E. de Pater, P. A. W. te Boekhorst   +8 more
wiley   +1 more source

Nucleic Acids as Emerging Regulators of Calcium Phosphate Biomineralization

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
Calcium phosphate biomineralization has traditionally been considered a protein‐regulated process. This review highlights the emerging role of nucleic acids, which interact with mineral phases through adsorption, coprecipitation, and templating, thereby influencing crystal nucleation and growth.
Fanny Duhalde, Jessem Landoulsi, Xavier Houard   +2 more
wiley   +1 more source

MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1

Oncology Reports, 2018
Breast cancer is the leading cause of cancer-related deaths in females worldwide. Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancer cases and has a poorer prognosis than other subtypes. Moreover, the treatment for breast cancer, especially for TNBC, remains unsatisfactory.
Wang, Yongxia, Zhang, Zheying, Wang, Jianqiang   +2 more
openaire   +3 more sources

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Biomedicines
Fibrodysplasia ossificans progressiva (FOP) is a debilitating genetic disorder characterized by recurrent episodes of heterotopic ossification (HO) formation in muscles, tendons, and ligaments.
Loreilys Mejias Rivera, Eileen M. Shore, Foteini Mourkioti   +2 more
doaj   +1 more source

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia

The Prostate, Volume 86, Issue 13, Page 1332-1340, September 15, 2026.
ABSTRACT Background Benign prostatic hyperplasia (BPH) leads to prostate enlargement and lower urinary tract symptoms that can resist treatment. A histologic hallmark of BPH is glandular epithelial hyperplasia with new ductal branching morphogenesis. The stromal inductive factors driving tissue morphogenesis may provide new therapeutic targets, but are
Anna S. Pollack, James D. Brooks, Jonathan R. Pollack   +2 more
wiley   +1 more source

A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date [PDF]

, 2011
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G>A ACVR1 mutation ...
Tobias, J. H., Triffitt, J. T., James T. Triffitt, Tobias, Jon H., Bullock, AN, Matthew A. Brown, Triffitt, James T., Hollingworth, P., Gregson, Celia L., Hollingworth, Peter, Gregson, CL, Brown, Matthew A., Bullock, A. N., Triffit, JT, Bullock, Alex N., Jon H. Tobias, Williams, Martin, Gregson, C. L., Petrie, KA, Alex N. Bullock, Williams, M., Petrie, K. A., Brown, MA, Hollingworth, P, Celia L. Gregson, Brown, M.A., Tobias, Jonathan H, Williams, M, Peter Hollingworth, Martin Williams, Kirsten A. Petrie, Petrie, Kirsten A.   +31 more
core   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, Volume 81, Issue 9, Page 3039-3070, September 2026.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
Franziska Roth‐Walter, Ian M. Adcock, Cristina Benito‐Villalvilla, Rodolfo Bianchini, Leif Bjermer, Gaetano Caramori, Luigi Cari, Kian Fan Chung, Zuzana Diamant, Ibon Eguiluz‐Gracia, Edward F. Knol, Milos Jesenak, Francesca Levi‐Schaffer, Giuseppe Nocentini, Liam O'Mahony, Oscar Palomares, Frank Redegeld, Milena Sokolowska, Betty Van Esch, Marco Zurlo, Cristiana Stellato   +20 more
wiley   +1 more source

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta, Zheyi Hu, Li Zhu, Lora Hamuro   +3 more
wiley   +1 more source

Unexpected Promotion of Bone Regeneration by Inhibition of BMPR1A‐Mediated BMP Signalling

Cell Proliferation, Volume 59, Issue 8, August 2026.
BMPR1A downregulation reduces ID1, releases TCF3 to activate GNG4‐PI3K‐AKT signalling, thereby promoting OPC proliferation and bone regeneration. ABSTRACT Bone morphogenetic protein (BMP) signalling plays a pivotal role in bone regeneration by regulating osteoprogenitor cell (OPC) function, and BMPs have been widely used in clinical treatment. However,
Zihao Zhou, Yun Zhai, Xiaochen Liu, Jiaojiao Shao, Jiani Zhou, Zhaoyang Li, Jiale He, Shuxian Lin, Qi Zhang   +8 more
wiley   +1 more source

Viability screen of ACVR1/ALK2 inhibitory compounds on Diffuse Intrinsic Pontine Glioma cells

, 2018
6 compounds developed by M4K Pharma to inhibit the ACVR1/ALK2 tyrosine kinase where tested for their ability to reduce viability of both mutant and wild-type ACVR1 DIPG cell lines (HSJD-DIPG-007 and HSJD-DIPG-011 respectively).
Bullock, Alex, Farnie, Gillian, Brown, Elizabeth   +2 more
core   +1 more source